Solid state, pulsed‐wave 355 nm UV laser atherectomy debulking in the treatment of infrainguinal peripheral arterial disease: The Pathfinder Registry
Catheterization and Cardiovascular Interventions · 2024
DOI: 10.1002/ccd.31023 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Catheterization and Cardiovascular Interventions, 2024. Verfasst von Tony S Das und 10 weiteren Autor:innen. Beteiligte Einrichtung: The Heart Hospital Baylor Plano, Plano, Texas, USA. Hauptthemen laut MEDLINE: Registries, Peripheral Arterial Disease, Atherectomy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AngioDynamics, Inc..
Abstract (Originalsprache)
Background
Atherectomy is an important option for debulking atherosclerotic plaque from diseased arteries in patients with infrainguinal arterial disease. Laser atherectomy uses a high‐powered laser to remove the plaque from the arteries to restore blood flow.
Aims
The Pathfinder multicenter registry was initiated to evaluate the safety and efficacy of the 355 nm laser atherectomy system in a real‐world setting for the treatment of de novo, re‐stenotic and in‐stent restenosis (ISR) lesions in infrainguinal arteries of patients with peripheral artery disease (PAD).
Methods
The study was a prospective, single‐arm, multicenter, open‐label registry study for patients treated with the 355 nm laser system. Clinical and lesion characteristics, procedural safety and efficacy data, and baseline, 6‐, and 12‐month outcomes data, including Ankle Brachial Index (ABI), Rutherford class, and Walking Impairment Questionnaires (WIQ), were collected. The primary efficacy endpoint was the achievement of ≤30% final residual stenosis at the index lesion postatherectomy and adjunctive therapy evaluated by an angiographic Core Lab. The primary safety endpoint was the percentage of subjects who did not experience periprocedural major adverse events (PPMAEs) before discharge.
Results
One hundred and two subjects with 121 lesions treated with the 355 nm laser device at 10 centers were included in the analysis. Mean age was 68.4 ± 10.21 years, 61.8% of subjects were male, 44.6% had critical limb ischemia (CLI), and 47.3% had tibial lesions. The mean residual stenosis at the end of the procedure was 24.4 ± 15.5 with 69 lesions (69.0%) achieving technical procedural success (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The Heart Hospital Baylor Plano, Plano, Texas, USA.
- Midwest Cardiovascular Research Foundation, Davenport, Iowa, USA.
- The Texas Cardiac and Vascular Institute, Corpus Christi, Texas, USA.
- Amavita Heart and Vascular Health, Miami, Florida, USA.
- Pulse Cardiovascular Institute, Scottsdale, Arizona, USA.
- Pima Heart and Vascular, Tucson, Arizona, USA.
ORCID-Profile: Tony S Das, Nicolas W Shammas, Jason A Yoho, Zaheed Tai, John Rundback
Förderung
- AngioDynamics, Inc.
Zitieren
APA
Das, T. S., Shammas, N. W., Yoho, J. A., Martinez-Clark, P., Ramaiah, V., Leon, L. R., Pacanowski, J. P., Tai, Z., Ali, V., Arslan, B., & Rundback, J. (2024). Solid state, pulsed‐wave 355 nm UV laser atherectomy debulking in the treatment of infrainguinal peripheral arterial disease: The Pathfinder Registry. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.31023
Vancouver
Das TS, Shammas NW, Yoho JA, Martinez-Clark P, Ramaiah V, Leon LR, et al. Solid state, pulsed‐wave 355 nm UV laser atherectomy debulking in the treatment of infrainguinal peripheral arterial disease: The Pathfinder Registry. Catheterization and Cardiovascular Interventions. 2024. doi:10.1002/ccd.31023
BibTeX
@article{Das2024,
author = {Das, Tony S and Shammas, Nicolas W and Yoho, Jason A and Martinez-Clark, Pedro and Ramaiah, Venkatesh and Leon, Luis R and Pacanowski, John P and Tai, Zaheed and Ali, Vaqar and Arslan, Bulent and Rundback, John},
title = {Solid state, pulsed‐wave 355 nm UV laser atherectomy debulking in the treatment of infrainguinal peripheral arterial disease: The Pathfinder Registry},
journal = {Catheterization and Cardiovascular Interventions},
year = {2024},
doi = {10.1002/ccd.31023}
}
EUVIMED